March 22nd 2023
Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.
Catherine A. Shu, MD, on Amivantamab Plus Lazertinib in Previously Treated EGFR+ NSCLC
September 20th 2022At ASCO 2022, Catherine A. Shu, MD, spoke about the CHRYSALIS-2 trial which investigated the use of amivantamab plus lazertinib in patients with EGFR-mutant non–small cell lung cancer following progression on a prior EGFR inhibitor.
ctDNA Reductions Associated With Improved Clinical Outcomes in NSCLC Treated With IO
September 16th 2022Findings from a pooled analysis indicated that a decrease in circulating tumor DNA was associated with improved clinical benefit in patients with non–small cell lung cancer treated with immune checkpoint inhibitors.
Hossein Borghaei, DO, MS, Discusses the Future of Biomarker Research for Immunotherapy in NSCLC
August 27th 2022In an interview with CancerNetwork®, Hossein Borghaei, DO, MS, details the promising body of ongoing research assessing biomarkers in patients with non–small cell lung cancer who are candidates for treatment with immunotherapy.